Ernexa Therapeutics Inc. Acquisition Costs, Period Cost
Ernexa Therapeutics Inc. (ERNA) reported Acquisition Costs, Period Cost of -$160.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AcquisitionCosts · last filed 2013-03-29
- Ernexa Therapeutics Inc. acquisition costs, period cost for the quarter ending 2012-12-31 was -$110.00K.
- Ernexa Therapeutics Inc. acquisition costs, period cost for the quarter ending 2012-09-30 was $0.00.
- Ernexa Therapeutics Inc. acquisition costs, period cost for fiscal 2012 was -$160.00K.
- Ernexa Therapeutics Inc. acquisition costs, period cost for fiscal 2011 was -$200.00K.
| Period end | Acquisition Costs, Period Cost 3 month | Acquisition Costs, Period Cost 6 month | Acquisition Costs, Period Cost 9 month | Acquisition Costs, Period Cost 12 month |
|---|---|---|---|---|
| 2012-12-31 | -$110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | -$110.00K derived: sum of 2 quarters · filed 2013-03-29 | -$160.00K 10-K · filed 2013-03-29 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$50.00K 10-Q · filed 2012-11-09 | ||
| 2012-06-30 | -$50.00K 10-Q · filed 2012-08-14 | |||
| 2011-12-31 | -$200.00K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |